HomeOur Focus AreasHIV & Hepatitis C

HIV & Hepatitis C


HIV and AIDS remain important challenges to community health, in large part because HIV is concentrated in specific communities, and often in communities with a history of social exclusion and stigmatization.

After decades of research, we still have no cure. If AIDS has taught us anything, however, it is that no community is an island. Health threats to any part of our world are threats to us all. At the REACH lab, we see HIV as an epidemic that reveals the ongoing role of social stratification and exclusion in the making and breaking of disease.

Recent Blog Posts for HIV and Hepatitis C

REACH researcher Roberto Abadie recently led a new publication on establishing trust among people who inject drugs when researching HIV

Memory Manda came to the University of Nebraska in January 2018 as a recipient of the National Institute of Health

Members of the REACH lab published a paper in Substance Use and Misuse in November titled "Injection Partners, HCV, and

Injection drug users are at exceedingly heightened risk for contracting infectious diseases like Hepatitis C and HIV, and risk behaviors

REACH graduate research assistant Ian Duncan presented at the annual American Society of Criminology conference in November. Duncan's presentation titled

Ongoing results of studies concerning the United States War on Drugs uncover how policies have raised the incarceration rates of

Funded Projects

Our work with HIV and hepatitis C research began with research involving agent-based simulation and modeling (“Injection Drug User Network Topologies and HIV Stabilization Dynamics” NIDA RC1 DA028476-01) and “Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” PI Holly Hagan, NYU; NIDA R01 DA034637. More recently we began a field project in Puerto Rico that combines these techniques with original data collection (“Injection Risk Networks in Rural Puerto Rico” NIDA R01 DA037117. In addition, for the last decade we have worked closely with Samuel Friedman, Holly Hagan, and Sheri Deren of the Center for Drug Use and HIV Research in New York City (NIDA P30 DA011041).